Insider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Purchases 17,600 Shares of Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock in a transaction on Tuesday, March 4th. The shares were bought at an average cost of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Trading Down 0.9 %

GUD opened at C$5.55 on Friday. The stock has a market cap of C$561.38 million, a price-to-earnings ratio of -18.53, a P/E/G ratio of -1,013.50 and a beta of 0.50. The stock’s 50 day moving average price is C$5.53 and its 200-day moving average price is C$5.56. Knight Therapeutics Inc. has a one year low of C$5.09 and a one year high of C$6.23. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.